Lesion-level analysis on OCT can help identify risk for atrophy, according to a speaker at Angiogenesis, Exudation, and Degeneration 2024.
SriniVas R. Sadda, MD, said the development of new therapies for age-related macular degeneration has made clinicians think about the next steps.
“We ultimately would like to intervene before the development of irreversible atrophy,” he said. “This means being able to identify AMD patients who are at the highest for progression.”
A retrospective cohort study included patients with non-neovascular AMD and incident complete retinal